Ciclesonide

According to the U.S. Food and Drug Administration (FDA), Ciclesonide has been approved for the treatment of allergic rhinitis and asthma ¹.

Ciclesonide is a corticosteroid medication used to treat seasonal and perennial allergic rhinitis symptoms ¹². These symptoms include sneezing, itching, and a runny nose ¹.

Ciclesonide is an effective treatment option for individuals who suffer from chronic asthma as it reduces airway inflammation and provides long-term relief ¹.

Here are some references that provide more information on the topic:

1. Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19
2. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
3. Ciclesonide | SpringerLink

Ciclesonide is an effective treatment option for individuals who suffer from chronic asthma as it reduces airway inflammation and provides long-term relief ¹.

Here are some references that provide more information on the topic:

1. Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19
2. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
3. Ciclesonide | SpringerLink

Ciclesonide is a corticosteroid that is primarily used to prevent asthma attacks in adults and children who are at least 12 years old ¹. Although it is not officially approved for the treatment of Chronic Obstructive Pulmonary Disease (COPD), there are reports indicating its potential to reduce inflammation associated with COPD ²³.

Here are some references that provide more information on the topic:

1. Inhaled Ciclesonide for Patients With Asthma or Chronic Obstructive Pulmonary Disease and COVID-19
2. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
3. Ciclesonide | SpringerLink
4. Alvesco (Ciclesonide) for COPD | MyCOPDTeam
5. Triple therapy in the management of chronic obstructive pulmonary disease
6. Ciclesonide inhalation Uses, Side Effects & Warnings - Drugs.com

Ciclesonide is a topical steroid that was developed to increase local bioavailability in the lung and reduce systemic exposure. Limited reports identify its use in patients with eosinophilic esophagitis. A retrospective cohort study of patients with EoE treated with Ciclesonide at a pediatric hospital from 2010 to 2019 found that Ciclesonide reduced symptoms, improved esophageal endoscopic appearance, and decreased epithelial inflammation without any severe side effects. The study concluded that Ciclesonide provides effective treatment for eosinophilic esophagitis with limited systemic exposure, thus potentially reducing the risk of adrenal suppression ¹.

¹: Nistel, M., Nguyen, N., Atkins, D., Miyazawa, H., Burger, C., Furuta, G. T., & Menard-Katcher, C. (2021). Ciclesonide impacts clinicopathological features of eosinophilic esophagitis. The Journal of Allergy and Clinical Immunology: In Practice, 9(10), 3725-3733.e2. link00792-3/pdf)

During the COVID-19 pandemic, some early studies have suggested that Ciclesonide may have a potential impact on reducing viral replication ¹. However, conclusive research is still needed to confirm these findings.

¹: A randomized clinical trial conducted by Horby et al. in 2021 found that the median time to alleviation of all COVID-19–related symptoms was 19.0 days (95% CI, 14.0-21.0) in the ciclesonide arm and 19.0 days (95% CI, 16.0-23.0) in the placebo arm. There was no difference in the resolution of all symptoms by day 30 (odds ratio, 1.28; 95% CI, 0.84-1.97) ¹. Another study conducted by Iwabuchi et al. in 2020 reported that ciclesonide inhalation may have therapeutic potential for COVID-19 pneumonia based on three cases ¹. However, further research is required to investigate whether these findings are replicable.

Here are the references for the above content:

¹ Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial | Adolescent Medicine | JAMA Internal Medicine | JAMA Network ¹